Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)
Historic Accumulated Expenses for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $16.0 million.
- Dianthus Therapeutics' Accumulated Expenses rose 10679.44% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 10679.44%. This contributed to the annual value of $13.1 million for FY2024, which is 10101.48% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Accumulated Expenses is $16.0 million, which was up 10679.44% from $14.0 million recorded in Q2 2025.
- Dianthus Therapeutics' Accumulated Expenses' 5-year high stood at $16.0 million during Q3 2025, with a 5-year trough of $3.2 million in Q2 2023.
- Over the past 4 years, Dianthus Therapeutics' median Accumulated Expenses value was $6.6 million (recorded in 2022), while the average stood at $8.1 million.
- Per our database at Business Quant, Dianthus Therapeutics' Accumulated Expenses plummeted by 4433.11% in 2023 and then soared by 13901.31% in 2025.
- Over the past 4 years, Dianthus Therapeutics' Accumulated Expenses (Quarter) stood at $6.6 million in 2022, then fell by 1.57% to $6.5 million in 2023, then surged by 101.01% to $13.1 million in 2024, then increased by 22.22% to $16.0 million in 2025.
- Its last three reported values are $16.0 million in Q3 2025, $14.0 million for Q2 2025, and $8.0 million during Q1 2025.